OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Paulson on When to Consider Lutathera in Patients With NETs

August 21st 2018

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses when to consider using Lutathera (lutetium Lu 177 dotatate) in patients with neuroendocrine tumors (NETs).

Dr. McCollum on Frontline Therapy for Patients With Metastatic CRC

August 21st 2018

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses frontline therapy for patients with metastatic colorectal cancer (mCRC).

Dr. Ansell Discusses the Role of PD-1 Blockade in Lymphoma

August 20th 2018

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the role of PD-1 blockade in lymphoma.

Dr. Becerra Discusses Regorafenib Dosing in Metastatic CRC

August 20th 2018

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses regorafenib (Stivarga) dosing in the treatment of patients with metastatic colorectal cancer.

Dr. Van Veldhuizen Reflects on the CARMENA Trial in RCC

August 20th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the impact of the CARMENA trial results in renal cell carcinoma.

Dr. Gandara on Treatment Options for Squamous Cell NSCLC

August 20th 2018

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, 2017 Giant of Cancer Care in Lung Cancer, discusses treatment options for patients with squamous cell non–small cell lung cancer.

Dr. Desai on Phase I Study of Entrectinib in Solid Tumors

August 20th 2018

Ami Vijay Desai, MD, assistant professor of Pediatrics, University of Chicago Comer Children's Hospital, discusses the design of a phase I study testing entrectinib in patients with solid tumors.

Dr. Lonial on CAR T-Cell Therapy in Myeloma

August 17th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.

Dr. Engel on the Future of Eltrombopag in HIV-Related Thrombocytopenia

August 17th 2018

Elissa Engel, MD, pediatric resident, University of South Florida, discusses the future of eltrombopag (Promacta) in HIV-related thrombocytopenia.

Challenges in the Treatment of Patients With MCL

August 17th 2018

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses challenges in the treatment of patients with mantle cell lymphoma (MCL).

Dr. Smith Discusses the Diagnosis of Double-Hit Lymphoma

August 17th 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses the diagnosis of double-hit lymphoma.

Dr. Kaplan on the Treatment of Pediatric Patients With Sarcoma

August 17th 2018

Rosandra N. Kaplan, MD, investigator, Pediatric Oncology Branch, Head, Tumor Microenvironment Section, National Cancer Institute, discusses the treatment of pediatric patients with sarcoma.

Overall Survival Analysis Between African-American and Caucasian Men with mCRPC

August 17th 2018

Susan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses an analysis of overall survival (OS) between African-American and Caucasian men with metastatic castration-resistant prostate cancer.

Dr. Savin on the Challenges of Developing Biosimilar Clinical Trials

August 17th 2018

Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the challenges that come with trying to develop a clinical trial for biosimilars.

Dr. Hardesty on Bevacizumab/PARP Inhibitor Combination in Ovarian Cancer

August 17th 2018

Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses the safety and efficacy of the bevacizumab/PARP inhibitor combination in ovarian cancer.

Dr. Borghaei on the FDA Approval of Nivolumab in Small Cell Lung Cancer

August 17th 2018

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the FDA approval of nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.

Dr. Matulonis Discusses QoL Data from GOG-258 in Endometrial Cancer

August 17th 2018

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the quality-of-life outcomes from the GOG-258 trial in patients with endometrial cancer.

Dr. Holstein Discusses Triplets and Quadruplets in Myeloma

August 17th 2018

Sarah Holstein, MD, PhD, associate professor, University of Nebraska Medical Center, discusses the use of triplets and quadruplets in the treatment of patients with multiple myeloma.

Dr. Bekaii-Saab Discusses the FDA Approval of Lenvatinib in HCC

August 16th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the FDA approval of lenvatinib (Lenvima) as a frontline systemic treatment for patients with advanced hepatocellular carcinoma (HCC).

Dr. Papadimitrakopoulou on Importance of More Targeted Therapies in NSCLC

August 16th 2018

Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the need for more targeted therapies in non–small cell lung cancer.